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ABSTRACT
Vaccine confidence reflects social, individual, and political factors indicating confidence in vaccines and 
associated health systems. In Japan, the government ceased proactive recommendation of the human 
papillomavirus (HPV) vaccine in June 2013, only several months after the recommendation had begun. 
Seven years later, as of October 2020, the suspension persists and vaccine coverage has precipitously 
declined, resulting in many young women being continually exposed to the risk of preventable HPV- 
related diseases. Accordingly, understanding stakeholder opinions on HPV vaccination issues is critical for 
informing strategies to improve HPV vaccine confidence and acceptance. In October 2019, we performed 
a nationwide, web-based survey of 1646 mothers of HPV-vaccination–eligible girls, 562 female adoles-
cents aged 15–19 years, and 919 healthcare professionals (HCPs) in Japan. This survey captured key 
elements of vaccine confidence (i.e., importance, effectiveness, and safety of the HPV vaccine), awareness, 
and the willingness to receive (in HPV-vaccination–eligible girls) or recommend (in HCPs) the HPV vaccine, 
and the factors responsible for these decisions. HPV vaccine confidence was generally higher among HCPs 
than among mothers or female adolescents. Nearly half of all stakeholders were neutral regarding their 
willingness to receive/recommend the HPV vaccine. The seriousness of cervical cancer and the HPV 
vaccine’s effectiveness or safety were important deciding factors for receiving/recommending the HPV 
vaccine. Besides these factors, sufficient information and free vaccination were crucial. Our results suggest 
several factors that could help shape public policy and communication strategies to improve HPV vaccine 
confidence and acceptance in Japan.
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Introduction
In Japan, in 2018, cervical cancer was the second most com-
mon cancer among women aged 15–44 years.1 Human papil-
lomaviruses (HPVs) cause almost all cases of cervical cancer 
and are implicated in various other cancers.1 Many countries 
have invested significant resources in HPV vaccination and 
other measures to promote cervical cancer elimination.2 In 
Japan, HPV vaccines have been commercially available since 
late 2009 and were introduced into the national immunization 
program (NIP) in April 2013.
Robust evidence supports the effectiveness and safety of 
HPV vaccines.3–7 Nonetheless, media reports about the occur-
rence of diverse symptoms in some HPV vaccine recipients in 
2013 led the Ministry of Health, Labour and Welfare (MHLW) 
in Japan to suspend their proactive recommendation for rou-
tine use of the HPV vaccine in the NIP just a few months after 
their recommendation began. The suspension persists. HPV 
vaccine coverage has sharply declined from approximately 70% 
to less than 1%.8 Among Japanese women born between 1994 
and 2007, an excess of 24,600–27,300 preventable cervical 
cancer cases and 5000–5700 cervical cancer deaths are 
projected to occur over their lifetime owing to the precipitous 
decline in HPV vaccination coverage recorded between 2013 
and 2019.9
Vaccine confidence is defined as trust in the importance, 
effectiveness, and safety of vaccines and the health system in 
which those are approved and delivered.10,11 Understanding 
and implementing effective approaches to restoring confidence 
in the HPV vaccine is critical to improving and sustaining 
vaccination acceptance to potentially avert adverse public 
health consequences.10 We therefore conducted a survey 
focused on understanding HPV vaccine confidence and the 
willingness to receive the HPV vaccine among Japanese 
mothers and female adolescents, and among healthcare profes-
sionals (HCPs) to recommend the HPV vaccine.
Methods
Study design
This was a nationwide, cross-sectional, web-based survey of 
mothers of HPV vaccination–eligible girls, female adolescents, 
and HCPs in Japan.
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Study populations
Mothers and female adolescents were recruited from a database 
managed by INTAGE Healthcare, Inc. (Tokyo, Japan). HCPs 
were recruited from a database managed by PLAMED, Inc. 
(Tokyo, Japan). Inclusion criteria included mothers who have 
at least one daughter aged 12–16 years, female adolescents aged 
15–19 years, and HCPs who are gynecologists (obstetricians/ 
gynecologists), pediatricians, or internists who had seen 
a female adolescent aged 12–19 years in clinical practice within 
the year prior to study participation. Although the recom-
mended age for HPV vaccination in Japan starts at 12 years, 
girls aged 12–14 years were excluded because of the respondent 
panel’s age restriction. Outcomes were assessed among (i) 
mothers who have daughters unvaccinated against HPV, (ii) 
female adolescents who have never received the HPV vaccine, 
and (iii) HCPs who currently do not recommend HPV vac-
cines to their patients aged 12–16 years. Factors associated with 
receiving or recommending the HPV vaccine were also 
assessed among mothers who have daughters vaccinated 
against HPV, female adolescents who have received the HPV 
vaccine, and HCPs who currently recommend HPV vaccines to 
their patients aged 12–16 years.
Outcomes
The primary outcome was measures of HPV vaccine confi-
dence (i.e., perceived importance, effectiveness, and safety of 
the HPV vaccine) and awareness of cervical cancer and the 
HPV vaccine among mothers, female adolescents, and HCPs. 
Secondary outcomes included HPV vaccination practices and 
the willingness to receive, have their daughters receive (for 
mothers), or (for HCPs) recommend the HPV vaccine, and 
factors associated with receiving or recommending the HPV 
vaccine, including timing and factors associated with accep-
tance of the HPV vaccine.
Study procedure and assessments
Potentially eligible respondents were randomly sampled and 
sent e-mail invitations with a web-link to participate in the 
study. A maximum of three reminders were sent to survey 
participants. An eligibility check was performed. The web- 
link included in the e-mail invitation directed participants to 
a webpage providing the following: (i) relevant study informa-
tion, (ii) the option to provide informed consent for study 
participation and data utilization for possible publication, 
and (iii) screening questions (i.e., approximately five items). 
Only participants who provided informed consent and met the 
inclusion/exclusion criteria were able to proceed and respond 
to the web-based study questionnaire. Respondents were 
allowed to respond to the questionnaire only once. Mothers 
with more than one daughter were requested to answer ques-
tions only for the daughter whose age was closest to 13 years. 
All respondents were asked basic demographic questions. The 
total number of items per respondent was approximately 30. 
The survey questionnaires were developed based on items in 
the Vaccine Confidence Index™ developed by the Vaccine 
Confidence Project as a tool for estimating vaccine confidence, 
against a mix of socio-demographic variables, and using a five- 
point Likert scale: Strongly agree, Tend to agree, Do not know, 
Tend to disagree, and Strongly disagree, for three domains of 
confidence.10,11 Other questions for this study were developed 
based on previous studies and modified for the situation in 
Japan.12,13 Question wording was finalized after a pilot study 
conducted from August 28 to 30, 2019, to ensure question 
accuracy and comprehensibility.
To prevent missing or out-of-range numerical values, 
restrictions were implemented on the online response entries. 
Upon completing the entire questionnaire, respondents 
received points that could be exchanged for various items, 
such as cash and gift cards.
Vaccine confidence was defined as a composite of answers 
to questions about the HPV vaccine, assessing vaccine impor-
tance, effectiveness, and safety. Other questions assessed levels 
of vaccine confidence regarding views on the importance, 
effectiveness, and safety of non–HPV vaccines, trust in the 
government to protect citizens from health risks, awareness 
of cervical cancer and the HPV vaccine, and factors associated 
with vaccination/recommendation. For mothers and adoles-
cents, adolescents’ HPV vaccination history was queried, as 
was HCPs’ current status for HPV vaccine recommendation.
Ethics approval
Respondents’ consent for study participation and data utiliza-
tion was obtained electronically by having them click 
a checkbox. The study protocol was approved by the ethics 
committee of Kitamachi Clinic (Tokyo, Japan; approval num-
ber: QVD06742), and the study was conducted in accordance 
with the Ethical Guidelines for Medical and Health Research 
Involving Human Subjects and the Act on the Protection of 
Personal Information in Japan. Under this act, surveys were 
anonymized to prevent personal information from being trace-
able by the sponsor to identify a specific individual.
Statistical analysis
The analysis was primarily descriptive in nature; thus, no 
formal hypothesis tests were conducted. For continuous vari-
ables, descriptive statistics (i.e., mean, standard deviation) were 
calculated. For categorical variables, the number and propor-
tion of respondents within each corresponding category were 
calculated. All statistical analyses were performed using SAS 
version 9.4 (SAS Institute) and R version 3.6.2 (R Core Team, 
2019). The proportions for each outcome were summarized 
descriptively in subgroups by each covariate. Pearson’s chi- 
square test was used to analyze statistical differences in the 
proportions for any comparisons between groups, with 
a P-value of <0.05 considered as statistically significant.
Results
The survey was conducted in October 2019, with 1646 
mothers, 562 female adolescents, and 919 HCPs included in 
the analysis populations. We describe vaccine confidence, 
awareness, and willingness to receive/recommend the HPV 
vaccine among 1591 mothers with daughters unvaccinated 
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against HPV, 466 female adolescents who had never received 
the HPV vaccine, and 548 HCPs who at the time of the survey 
did not recommend the HPV vaccine to their patients. For all 
respondents, the factors that determined their decisions were 
assessed (Figure 1). Tables 1–3 show the respondents’ demo-
graphic and background information.
Vaccine confidence
Positive endorsement (i.e., “Tend to agree” or “Strongly agree”) on 
the importance, effectiveness, and safety of the HPV vaccine was 
reported by 24%, 25%, and 11% of mothers; 49%, 46%, and 34% of 
female adolescents; and 83%, 84%, and 52% of HCPs, respectively 
(P< .001). Mothers (46%–54%) and female adolescents (36%– 
40%) most commonly selected “Do not know” for questions 
related to the three factors of vaccine confidence (Figure 2).
Levels of HPV vaccine confidence were higher among 
female adolescents in the Chugoku region than in other regions 
(Supplementary Figure 1). Views on vaccines and vaccination 
in infants/toddlers and adolescents are shown in 
Supplementary Figure 2. The levels of confidence in non– 
HPV vaccines were higher than those in the HPV vaccine.
Ten percent of mothers and 18% each of female adolescents 
and HCPs agreed with the statement, “The information about 
HPV vaccines from the government is sufficient” (Supplementary 
Figure 3).
Awareness
Positive response (i.e., “I know about it to some extent” or 
“I know about it in detail”) to the awareness of cervical 
cancer and the HPV vaccine was reported by 61% and 
44% of mothers, 27% and 16% of female adolescents, and 
90% and 86% of HCPs, respectively (P<.001 for both 
items). Approximately one-third of female adolescents 
were not aware of the HPV vaccine (Figure 3). Female 
adolescents who knew about HPV vaccines in detail or to 
some extent had low confidence in HPV vaccine impor-
tance (Supplementary Figure 4). Levels of confidence in 
HPV vaccine effectiveness and safety exhibited similar 
trends (data not shown). There were no large differences 
among female adolescents regarding the information 
source influencing these trends (data not shown). 
However, more female adolescents with higher awareness 
had low confidence in HPV vaccine importance and 
thought, “HPV vaccine recommendations are currently 
revoked because of potential safety issues” than female 
adolescents with high confidence in HPV vaccine impor-
tance (data not shown).
Among HCPs, there were differences across medical 
specialization regarding awareness of the HPV vaccine. 
Sixty-seven percent of general practitioner (GP) gynecolo-
gists and 71% of hospital physician (HP) gynecologists— 
more than twice the proportion of any other specialists— 
Figure 1. Study flow diagram. Mothers who have ≥1 daughter aged 12–16 years and female adolescents aged 16–19 years were randomly sampled given the large 
number of such individuals registered in the database, but e-mail invitations were sent to all female adolescents aged 15 years who were registered in the database. 
Gynecologists/obstetricians, pediatricians, and internists were randomly sampled.  
*As reflected by answers of “Willing” or “Very willing.” **As reflected by an answer of “Do not know.” ***As reflected by answers of “Not willing” or “Very unwilling.” 
HCP = healthcare professional; HPV = human papillomavirus.
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answered that they knew about the HPV vaccine in detail. 
Eleven percent of HP internists, 58% of GP pediatricians, 
and 32%–55% of other specialists knew that the HPV vac-
cine is included in Japan’s NIP.
Willingness to receive or recommend the HPV vaccine
Among mothers and female adolescents, 9% and 23%, respec-
tively, were willing to receive the HPV vaccine, whereas 43% of 
HCPs were willing to recommend the HPV vaccine (P<.001). 
However, neutral willingness (answer “Do not know”) was the 
largest proportion in all groups (Figure 4). Respondents with 
higher HPV vaccine confidence were more willing to receive or 
recommend the HPV vaccine (Supplementary Figure 5).
Reasons and sources of information for the decision to 
receive/recommend the HPV vaccine
The main reasons why mothers chose to have their daughters 
vaccinated were because they thought HPV vaccines are effective 
(45%) and cervical cancer is dangerous (36%; Supplementary 
Table 1). The mother’s recommendation was the main reason 
for female adolescents having received the HPV vaccine 
(Figure 5(a); Supplementary Table 2). At the time of the survey, 
40% of HCPs recommended HPV vaccination to their female 
adolescent patients. HCPs stated that they currently recommend 
HPV vaccination because of its effectiveness (96%), the seriousness 
of cervical cancer (83%), and their belief that HPV vaccines are safe 
(59%; Figure 5(a); Supplementary Table 3). “Safety concerns” and 
“insufficient information” were the main drivers among the sta-
keholders for vaccine refusal or lack of recommendation 
(Figure 5(b); Supplementary Tables 4–6).
Figure 6 shows sources of information used by mothers and 
female adolescents to decide whether or not to get vaccinated 
against HPV or, for HCPs, whether to recommend HPV 
Table 1. Demographic and baseline characterstics of mothers (n=1646).
n (%)
Age of mothers, years
Mean±SD 45.5±4.8
















Middle school 29 (2)
High school 477 (29)
Short training or college degree 669 (41)
University 415 (25)
Graduate school and above 32 (2)
Other than the above 4 (0)
Do not want to respond 20 (1)
Employment status
Employed 773 (47.0)
Self-employed or enterprise manager 51 (3.1)
Full-time homemaker 691 (42.0)
Student 2 (0.1)
Other than the above 129 (7.8)
SD = standard deviation.
Table 2. Demographic and baseline characterstics of female adolescents (n=562).
n (%)
















Current educational level or employment status
Middle school 3 (1)
High school 364 (65)
Short training or college degree 30 (5)
University 117 (21)
Employed 12 (2)
Self-employed or enterprise manager 0 (0)
Full-time homemaker 6 (1)
Other than the above 30 (5)
SD = standard deviation.
Table 3. Demographic and baseline characterstics of HCPs (n=919).
n (%)























Vaccination history of patients
Do you recommend any vaccines, including HPV vaccines?
Yes, and consequently most patients get vaccinated 576 (63)
Yes, but most patients do not get vaccinated 148 (16)
No, but most patients get vaccinated 87 (10)
No, and most patients do not get vaccinated 108 (12)
HCP = healthcare professional; HPV = human papillomavirus.
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vaccination. HCPs who selected television (TV) news or health- 
related programs as their primary source of information were 
less willing to recommend the HPV vaccine. Among sources of 
information (multiple answers possible) used to decide whether 
or not to receive the HPV vaccine, TV news or health-related 
programs were used by 43%–77% of mothers and 20%–54% of 
female adolescents; social networking services or video-sharing 
sites were indicated by 3%–5% in both groups (Supplementary 
Table 7; see also Supplementary Table 8).
Sixty percent each of HCPs who currently recommend 
the HPV vaccine and HCPs who do not but stated their 
willingness to do so reported that they would recommend 
the HPV vaccine based on patient inquiry (Figure 7). 
Supplementary Tables 9 and 10 show sources of informa-
tion used by HCPs to decide whether or not to recommend 
the HPV vaccine. Almost 60% of the mothers willing to 
have their daughters receive the HPV vaccine and approxi-
mately one-third of the female adolescents expressed 
Figure 2. HPV vaccine confidence. HPV vaccine importance: “Overall, I think HPV vaccines are important to have”; HPV vaccine effectiveness: “Overall, I think HPV 
vaccines are effective”; HPV vaccine safety: “Overall, I think HPV vaccines are effective.” *Mothers who have daughters unvaccinated against HPV. **Female adolescents 
who never received the HPV vaccine. ***HCPs who do not currently recommend HPV vaccination to their patients. P<.001 for between-group comparison for the 
proportions of “Tend to agree” and “Strongly agree.” HCP = healthcare professional; HPV = human papillomavirus.
Figure 3. Awareness of cervical cancer and the HPV vaccine. *Mothers who have daughters unvaccinated against HPV. **Female adolescents who never received the 
HPV vaccine. ***HCPs who do not currently recommend HPV vaccination to their patients. P<.001 for between-group comparison for the proportions of “I know about it 
to some extent” and “I know about it in detail for both items.” HCP = healthcare professional; HPV = human papillomavirus.
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a positive opinion (i.e., endorsement of “Immediately” or 
“By the end of the routine, free vaccination period”) 
regarding the timing of vaccination (Figure 8).
Discussion
This is the first nationwide, comprehensive survey on vaccine 
confidence related to HPV vaccination in Japan conducted 
Figure 4. Willingness to receive or recommend the HPV vaccine. *Mothers who have daughters unvaccinated against HPV. **Female adolescents who never received the 
HPV vaccine. ***HCPs who do not currently recommend HPV vaccination to their patients. P<.001 for between-group comparison for the proportions of “Willing” to 
receive or recommend the HPV vaccine. HCP = healthcare professional; HPV = human papillomavirus.
Figure 5. (a) Reasons for having received or to recommend the HPV vaccine (multiple answers allowed), and (b) reasons for not to decide to have received or not to 
decide to recommend the HPV vaccine (multiple answers allowed). Main reasons present only those items that had a response rate of 20% or more in at least one of the 
three groups. Please refer to supplementary tables for further details on all items. HCP = healthcare professional; HPV = human papillomavirus.
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since the 2013 suspension of the government’s proactive HPV 
vaccine recommendation. Collectively, the findings could help 
inform the development of effective public health communica-
tions, public engagement, and advocacy campaigns that could 
lead to greater awareness of, confidence in, and improved 
uptake of the HPV vaccine in Japan.
Key findings are that HPV vaccine confidence and willing-
ness to receive/recommend the HPV vaccine were higher 
among HCPs than among mothers and female adolescents 
(P<.001). Among mothers, HPV vaccine confidence regarding 
safety was slightly lower than that for effectiveness and impor-
tance. Overall, respondents with high HPV vaccine confidence 
were more willing to receive/recommend the HPV vaccine. 
The seriousness of cervical cancer, the HPV vaccine’s effective-
ness and safety, sufficient information, and free HPV vaccina-
tion were important factors for respondents’ decisions to 
receive/recommend the HPV vaccine. Sixty percent of HCPs 
who currently recommend the HPV vaccine or who were 
willing to do so each reported that they would recommend it 
based on patient inquiry. As patients rarely ask their physicians 
about the HPV vaccine, this result indicates that HCPs are not 
necessarily recommending the HPV vaccine proactively or that 
often.
With regard to the timing of HPV vaccination, the results 
suggest that female adolescents’ intention to receive the HPV 
vaccine was lower than that of mothers to have their daughters 
receive the vaccine. Overall, results indicate female adolescents 
as being less eager for HPV vaccination, although this could 
also reflect their lack of awareness and possibly their relative 
inaction compared with their mothers.
The most common reason for neutral willingness of vacci-
nation among mothers and female adolescents was “insuffi-
cient information.” In fact, approximately one-third of the 
female adolescents were not aware of the HPV vaccine. 
Moreover, with the current stand of the Japanese government 
to withhold resumption of proactive recommendation of the 
Figure 6. Sources of information used to decide whether (a) or not (b) to receive or recommend the HPV vaccine (multiple answers allowed). Main sources of 
information present only those items that had a response rate of 20% or more in at least one of the three groups. Please refer to supplementary tables for further details 
on all items. HCP = healthcare professional; HPV = human papillomavirus; MHLW = Ministry of Health, Labour and Welfare; TV = television.
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HPV vaccine in the NIP and HCPs not recommending the 
vaccine proactively, it could be expected that mothers and 
female adolescents were unable to decide on HPV vaccination.
Converging sources of evidence in Japan4–7 and globally3 
support the high effectiveness of the HPV vaccine against HPV 
infection, cervical cancer, and related diseases. Our results thus 
underscore gross disparities between the perceptions of key 
stakeholders and actual vaccine risks. For example, the HPV 
vaccine has been shown to be safe and not causally associated 
with the adverse events publicized by the media.14–16 
Figure 7. Timing of recommendation for HCPs who currently recommend or who are willing to recommend the HPV vaccine (in response to the question, “When would you 
like to recommend HPV vaccines to your patients?”). When the HCPs who recommend HPV vaccines “Anytime even if patients would not ask me about HPV vaccines” and 
those who recommend “When patients ask me about the vaccines” were asked their reasons, there were differences of more than 15 points between these two groups with 
regard to “Safety (I think HPV vaccines are safe),” “Sufficient information (We know enough about HPV vaccines),” and “Routine vaccination (HPV vaccines are free for girls of 
an HPV vaccine–eligible age).” HCP = healthcare professional; HPV = human papillomavirus; MHLW = Ministry of Health, Labour and Welfare.
Figure 8. Timing of HPV vaccination for mothers who are willing to have their daughters receive the HPV vaccine (when asked, “When would you like to have your 
daughter(s) receive HPV vaccines?”) and female adolescents who are willing to receive the HPV vaccine (when asked, “When would you like to receive the HPV 
vaccine?”). HPV = human papillomavirus.
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Nonetheless, proactive recommendation of the HPV vaccine 
by the MHLW remains suspended, despite recommendations 
by the Japan Expert Council on Promotion of Vaccination.17 
Numerous other countries have devoted substantial resources 
to HPV vaccination and other strategies to facilitate cervical 
cancer elimination.2 Given the high stakes involved in Japan, 
swift political action has been urged.18
A 2018 internet-based public opinion survey administered 
throughout Japan to 1000 men and women aged >20 years 
reported that <30% of respondents had basic knowledge about 
the HPV vaccine and 67% could not decide whether or not 
HPV vaccination should be recommended.19 Among Japanese 
physicians, 90% indicated that they would restart vaccinating 
adolescents against HPV if the MHLW resumed their proactive 
recommendation of the vaccine.20 Similar results are supported 
by other studies,21 including regarding mothers’ perception of 
the HPV vaccine and their intentions to have their daughters 
vaccinated.22,23 Acceptance of the HPV vaccine was higher 
among parents working in healthcare, who were knowledge-
able about the HPV vaccine and cervical cancer.22 Clear and 
unbiased information about HPV, cervical cancer, and the 
HPV vaccine, along with proactive recommendation by the 
MHLW, could thus be key determinants of parents’ and female 
adolescents’ willingness to accept HPV vaccination. This is 
especially true given that although trust in doctors and nurses 
in Japan is generally high, confidence in vaccines is low, under-
scoring wider issues relating to trust in the government and 
their policies.24
Previous surveys19–23 confirm the low levels of public trust, 
interest, and awareness of the HPV vaccine among parents, 
adolescents, and HCPs in Japan, although no nationwide data 
on HPV vaccine confidence and willingness with its timing 
have been published. Thus, investigating HPV vaccine confi-
dence nationwide across Japan among the three important 
stakeholders—mothers, female adolescents, and HCPs—and 
identifying the factors that determine their willingness to 
receive or (for HCPs) recommend the HPV vaccine are crucial 
to better understand behavioral motives and the dynamics of 
the interaction and communication between them that could 
in turn be addressed by tailored interventions.
Public trust and confidence in the HPV vaccine and its 
providers, as well as in the vaccination process, development 
policies, and recommendation, are at the core of increasing 
vaccine acceptance and implementing successful immuniza-
tion programs. Our results reveal the current state of HPV 
vaccine confidence in Japan and its possible determinants. 
Such evidence could help shape public policy and communica-
tion strategies to improve HPV vaccine confidence and accep-
tance in Japan.
We found that the level of awareness/understanding and 
type and source of information shape perception of the HPV 
vaccine. HCPs recommending the HPV vaccine or who were 
willing to do so relied on background scientific knowledge 
more than other sources of information. Moreover, HCPs 
who referred to scientific information showed high acceptance 
of the HPV vaccine. By contrast, HCPs, as well as mothers and 
female adolescents who were negative about the HPV vaccine, 
were more likely to be influenced by media reporting. Both 
mothers and female adolescents selected “TV news or health- 
related programs” as the most frequently used source of infor-
mation. Mothers willing to recommend the HPV vaccine were 
influenced by information from the local government and 
HCPs.
A high proportion of the HCPs we surveyed were not even 
aware that the HPV vaccine is included in the NIP. Based on 
these results, better public communication is needed around 
the availability of the HPV vaccine in the NIP. HCPs who were 
asked about the reasons for recommending the HPV vaccine 
reported that safety, sufficient information, routine (free) vac-
cination, and care and support after vaccination were the most 
important.
Since mothers’ and female adolescents’ reliance on informa-
tion about the safety and effectiveness of the HPV vaccine can 
influence willingness to receive the HPV vaccine, all stake-
holders should be given sufficient and appropriate information 
about the HPV vaccine. Findings from this study could help 
shape public policy and communication strategies to improve 
future HPV vaccine confidence and acceptance in Japan and 
ultimately increase HPV vaccination rates to avert the rising 
trend of cervical cancer.9 Including the HPV vaccine along 
with routine adolescent vaccinations has been shown in the 
United States to be a key determinant of HPV vaccination 
rates.25 We found that many mothers, female adolescents, 
and HCPs have higher confidence in vaccines for infants and 
toddlers compared with the HPV vaccine.
Because of the differences between Japan and other coun-
tries regarding HPV vaccine policy, some of our results may 
not be widely generalizable. Within Japan, however, both 
INTAGE and PLAMED databases have similar patterns of 
distribution of age, gender, geographic locations, and clinical 
departments as nationwide data. The selected database popula-
tions are not expected to greatly differ from the target Japanese 
populations because the database from INTAGE Healthcare, 
Inc.26 (as of October 2018) consisted of approximately 
9,850,000 individuals in Japan and that of PLAMED, Inc.27 
(as of April 2016) consisted of approximately 45,400 doctors 
from 37 medical departments in Japan. The analysis popula-
tion included 34 female adolescents who reported that they had 
received the HPV vaccine at the age of 9 years or 10 years— 
ages ineligible for the routine vaccination program in Japan. 
Results excluding these respondents were similar to those that 
included them (data not shown).
Several limitations should be noted. Respondents’ charac-
teristics might be different from those of the general population 
because people without internet access were not included, nor 
were females aged 12–14 years. Mothers, females aged 
16–19 years, and HCPs were randomly sampled given the 
large number of such individuals registered in the database. 
In contrast, all registered females aged 15 years received an 
e-mail invitation because of the relatively small number of such 
individuals in the database. Response bias may have occurred 
in this study as it is likely that individuals who responded to the 
questionnaire had an interest in the research area compared 
with those who did not, which could distort the samples’ 
representativeness. The causal relationships between factors 
associated with the intentions of the respondents cannot be 
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determined because of the cross-sectional nature of this study. 
Additionally, the intended willingness to receive or recom-
mend the HPV vaccine may not reflect actual behavior. An 
important clinical question revealed by the current study is 
what can bridge the gap between willingness and behavior.
In conclusion, levels of HPV vaccine confidence were higher 
among HCPs than among mothers and female adolescents. 
The seriousness of cervical cancer and perceptions of HPV 
vaccine effectiveness and safety were the most important fac-
tors among all stakeholders for the decision to receive/recom-
mend the HPV vaccine. Mothers and female adolescents were 
more likely to be influenced by media reporting, but some of 
them indicated the desire to get information from HCPs. Given 
that patients rarely ask their physicians about the HPV vaccine, 
this represents an impediment to HCPs recommending the 
HPV vaccine in the future. This is because HCPs stated that 
their willingness to recommend the HPV vaccine would be 
based on patient inquiry. This thus represents another gap 
that could be addressed through future interventions. Overall, 
our survey results suggest the existence of several critical fac-
tors that could change the perception and behavior around 
HPV vaccination. These in particular include resumption of 
a proactive recommendation by the MHLW and HCP 
recommendation.
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